富马酸丙酚替诺福韦治疗慢性乙型肝炎疗效的影响因素分析  

Analysis of influencing factors on the efficacy of tenofovir alafenamide fumarate in the treatment of chronic hepatitis B

作　　者：关善斌 张文涛[1] 郭卉[1] GUANG Shanbin;ZHANG Wentao;GUO Hui(National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Department of Hepatobiliary,the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin,300381,China)

机构地区：[1]天津中医药大学第一附属医院肝胆科国家中医针灸临床医学研究中心,天津300381

出　　处：《中国中西医结合消化杂志》2022年第9期655-658,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：目的:初步探讨在慢性乙型病毒性肝炎(CHB)患者口服富马酸丙酚替诺福韦(TAF)病毒治疗过程中(第24周、48周),影响TAF抗病毒治疗效果的因素。方法:选择2020年4月-2022年1月在门诊或住院的CHB患者为研究对象,回顾性分析其临床资料,根据纳入、排除标准筛选出57例有完整临床资料的CHB患者,分为完全应答组和未完全应答组,运用修正Poissoin回归进行统计分析处理。结果:在抗病毒第24周时,单因素回归中,基线HBV DNA、基线HBsAg、患者之前是否采用过其他抗病毒药物对抗病毒作用差异有统计学意义,多因素回归分析中提示基线HBV DNA差异有统计学意义;在抗病毒治疗第48周时,单因素回归分析提示基线HBV DNA、基线HBsAg差异有统计学意义,多因素回归提示基线HBV DNA差异有统计学意义。结论:CHB患者在口服TAF抗病毒过程中,在第24周、48周时,CHB患者的基线HBV DNA水平可以预测抗病毒的治疗效果。Objective: To initially investigate the factors influencing the efficacy of tenofovir alafenamide fumarate(TAF)antiviral therapy during the course(24 weeks and 48 weeks)of tenofovir alafenamide fumarate(TAF)viral therapy in patients with chronic viral hepatitis B(CHB patients).Methods: Patients with CHB who were outpatients or inpatients in the Hospital between April 2020 and January 2022 were selected as the study subjects,and their clinical data were retrospectively analyzed.According to the inclusion and discharge criteria,a total of 57 CHB patients with complete clinical data were screened into fully responsive and incompletely responsive groups,which were processed for statistical analysis using modified Poissoin regression.Results: It shows that there are statistical differences in baseline HBV DNA,baseline HBsAg and whether the patient has used other antiviral drugs before in the univariate regression at the 24th week of antiviral treatment.The multivariate regression analysis shows that there are statistical differences in baseline HBV DNA.At the 48th week of antiviral treatment,the univariate regression analysis shows that there are statistical differences in baseline HBV DNA and baseline HBsAg,Multivariate regression showed that there was a significant difference in baseline HBV DNA.Conclusion: It shows that the baseline HBV DNA level of CHB patients can predict the antiviral treatment effect at 24 and 48 weeks.

关 键 词：慢性乙型病毒性肝炎 富马酸丙酚替诺福韦 影响因素 

分 类 号：R575.1[医药卫生—消化系统]